World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
130
Citations
82171
World Ranking
2446
National Ranking
1383

Lajos Pusztai publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Lajos Pusztai sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 904 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Lajos Pusztai D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Lajos Pusztai sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 130 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Lajos Pusztai is affiliated with Yale University in the United States and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research is primarily situated within oncology, with a particular focus on breast cancer treatment studies, cancer immunotherapy and biomarkers, and cancer genomics and diagnostics.

Their work spans several subfields, including oncology, cancer research, pulmonary and respiratory medicine, molecular biology, and genetics. Key research topics include advanced breast cancer therapies, HER2/EGFR in cancer research, cancer treatment and pharmacology, as well as cancer cells and metastasis.

Pusztai has authored numerous publications in prominent scientific venues. The most frequent publication venues include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • npj Breast Cancer

Some recent notable papers provide insight into the spectrum of their research interests:

  • "Pembrolizumab for Early Triple-Negative Breast Cancer," 2020, New England Journal of Medicine
  • "Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer," 2020, JAMA Oncology
  • "Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up," 2023, Annals of Oncology
  • "Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer," 2023, Journal of Clinical Oncology
  • "Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue," 2022, JAMA Oncology

In terms of collaboration, Pusztai often works with a consistent group of co-authors, including:

  • William E. Barlow
  • Kathy S. Albain
  • Kim Blenman
  • Christina Yau
  • Laura J. Esserman

Their extensive research reflects a strong emphasis on breast cancer-related studies and cancer immunotherapy, supporting ongoing advancements in treatment strategies and diagnostic approaches. The combination of clinical and molecular work underscores the multidisciplinary nature of their scientific contributions.

Best Publications

  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

    Cornelia Liedtke;Chafika Mazouni;Kenneth R. Hess;Fabrice André

  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim

  • The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

    Leming Shi;Laura H. Reid;Wendell D. Jones;Richard Shippy

  • Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

    Garrett M Frampton;Alex Fichtenholtz;Geoff A Otto;Kai Wang

  • Pembrolizumab for Early Triple-Negative Breast Cancer.

    Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur

  • Gene-expression signatures in breast cancer.

    Christos Sotiriou;Lajos Pusztai

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

    W. Fraser Symmans;Florentia Peintinger;Christos Hatzis;Radhika Rajan

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

    José Baselga;José Baselga;Ian Bradbury;Holger Eidtmann;Serena Di Cosimo;Serena Di Cosimo

  • Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

    Rita R Nanda;Laura Q M Lq Chow;Claire Dees;Raanan R Berger

  • The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

    Jeffrey S. Ross;Elzbieta A. Slodkowska;W. Fraser Symmans;Lajos Pusztai

  • An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

    Katherine Stemke-Hale;Ana Maria Gonzalez-Angulo;Ana Lluch;Richard M. Neve

  • The Microarray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

    Leming Shi;Gregory Campbell;Wendell D. Jones;Fabien Campagne

  • Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

    Antonella Sistigu;Takahiro Yamazaki;Erika Vacchelli;Kariman Chaba

  • Cancer heterogeneity: implications for targeted therapeutics

    R Fisher;L Pusztai;C Swanton;C Swanton

  • The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

    Jeffrey S. Ross;Jeffrey S. Ross;Jonathan A. Fletcher;Gerald P. Linette;Gerald P. Linette;James Stec

  • Gene expression profiling in breast cancer: classification, prognostication, and prediction

    Jorge S Reis-Filho;Lajos Pusztai

  • Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

    Kenneth R. Hess;Keith Anderson;W. Fraser Symmans;Vicente Valero

  • Triple-negative breast cancer—current status and future directions

    O. Gluz;C. Liedtke;N. Gottschalk;L. Pusztai

  • Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

    Francisco J. Esteva;Vicente Valero;Daniel Booser;Laura T. Guerra

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
W. Fraser Symmans
W. Fraser Symmans The University of Texas MD Anderson Cancer Center
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Francisco J. Esteva
Francisco J. Esteva New York University
David L. Rimm
David L. Rimm Yale University
Kenneth R. Hess
Kenneth R. Hess The University of Texas MD Anderson Cancer Center
Jeffrey S. Ross
Jeffrey S. Ross Foundation Medicine
Massimo Cristofanilli
Massimo Cristofanilli Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in Medicine but exploring other flexible pathways? The growing field of online health education offers diverse degree options that complement a traditional MD or serve as alternative routes for healthcare careers.

For those passionate about wellness and preventive care, a best online nutrition degree opens doors to roles in community health, food sciences, or dietary planning. Aspiring healthcare leaders may consider pursuing advanced qualifications through top online mha programs that are cahme accredited, which prepare graduates for management positions in hospitals and health systems.

Registered Nurses seeking career advancement can benefit from rn to bsn no clinical hours programs, allowing diploma or associate degree nurses to earn a bachelor’s degree online without additional clinical requirements. For nurses with a master’s degree, there are also accelerated msn to dnp programs, designed to fast-track a transition to top clinical and leadership roles.

Each pathway provides unique opportunities, balancing flexibility, specialization, and advancement within the ever-evolving healthcare landscape.

Best Scientists Citing Lajos Pusztai

Trending Scientists

Recently Published Articles